Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas

Naoko Tsuyama, Daisuke Ennishi, Masahiro Yokoyama, Satoko Baba, Reimi Asaka, Yuko Mishima, Yasuhito Terui, Kiyohiko Hatake, Kengo Takeuchi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Expression of T-cell markers, generally investigated for immunophenotyping of T-cell lymphomas, is also observed in several types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We previously reported that CD5 expression in DLBCL is an inferior prognostic factor in the era of rituximab. However, data regarding the frequencies, histological relevance, and prognostic importance of T-cell markers other than CD5 are currently unavailable. In the present study, we comprehensively evaluated the expression of T-cell markers (CD2, CD3, CD4, CD5, CD7, and CD8) in 501 B-cell lymphomas, including 225 DLBCLs, by flow cytometry and subsequent immunohistochemistry. T-cell markers other than CD5, such as CD2, CD4, CD7, and CD8, were expressed in 27 (5%) patients, and notably, all of these cases were classified as large B-cell lymphoma subtypes: 25 DLBCLs and 2 intravascular large B-cell lymphomas. CD5 and other T-cell markers were expressed in 15% (31/225) and 10% (25/225) of DLBCL cases, respectively. Five of them co-expressed CD5 and other T-cell markers. Retrospectively analyzing the prognostic relevance of T-cell markers in 169 patients with primary DLBCL treated with rituximab-based chemotherapy, we showed that only CD5 was a strong predictor of poor survival. This study provides information about the occurrence of T-cell markers other than CD5 in B-cell lymphomas, their frequent histological subtypes, and their prognostic significance in DLBCL. CD5 was reconfirmed as a negative prognostic marker in DLBCL patients receiving rituximab-inclusive chemotherapy, whereas T-cell markers other than CD5 were found to have no impact on clinicopathological and survival analyses.

Original languageEnglish
Pages (from-to)33487-33500
Number of pages14
JournalOncotarget
Volume8
Issue number20
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
T-Lymphocytes
Drug Therapy
Immunophenotyping
T-Cell Lymphoma
Survival Analysis
Flow Cytometry
Immunohistochemistry
Survival

Keywords

  • Aberrant expression
  • CD5
  • CD8
  • Diffuse large B-cell lymphoma
  • T-cell marker

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas. / Tsuyama, Naoko; Ennishi, Daisuke; Yokoyama, Masahiro; Baba, Satoko; Asaka, Reimi; Mishima, Yuko; Terui, Yasuhito; Hatake, Kiyohiko; Takeuchi, Kengo.

In: Oncotarget, Vol. 8, No. 20, 01.01.2017, p. 33487-33500.

Research output: Contribution to journalArticle

Tsuyama, Naoko ; Ennishi, Daisuke ; Yokoyama, Masahiro ; Baba, Satoko ; Asaka, Reimi ; Mishima, Yuko ; Terui, Yasuhito ; Hatake, Kiyohiko ; Takeuchi, Kengo. / Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas. In: Oncotarget. 2017 ; Vol. 8, No. 20. pp. 33487-33500.
@article{9836401ddf0d44bab0da2e3013088875,
title = "Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas",
abstract = "Expression of T-cell markers, generally investigated for immunophenotyping of T-cell lymphomas, is also observed in several types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We previously reported that CD5 expression in DLBCL is an inferior prognostic factor in the era of rituximab. However, data regarding the frequencies, histological relevance, and prognostic importance of T-cell markers other than CD5 are currently unavailable. In the present study, we comprehensively evaluated the expression of T-cell markers (CD2, CD3, CD4, CD5, CD7, and CD8) in 501 B-cell lymphomas, including 225 DLBCLs, by flow cytometry and subsequent immunohistochemistry. T-cell markers other than CD5, such as CD2, CD4, CD7, and CD8, were expressed in 27 (5{\%}) patients, and notably, all of these cases were classified as large B-cell lymphoma subtypes: 25 DLBCLs and 2 intravascular large B-cell lymphomas. CD5 and other T-cell markers were expressed in 15{\%} (31/225) and 10{\%} (25/225) of DLBCL cases, respectively. Five of them co-expressed CD5 and other T-cell markers. Retrospectively analyzing the prognostic relevance of T-cell markers in 169 patients with primary DLBCL treated with rituximab-based chemotherapy, we showed that only CD5 was a strong predictor of poor survival. This study provides information about the occurrence of T-cell markers other than CD5 in B-cell lymphomas, their frequent histological subtypes, and their prognostic significance in DLBCL. CD5 was reconfirmed as a negative prognostic marker in DLBCL patients receiving rituximab-inclusive chemotherapy, whereas T-cell markers other than CD5 were found to have no impact on clinicopathological and survival analyses.",
keywords = "Aberrant expression, CD5, CD8, Diffuse large B-cell lymphoma, T-cell marker",
author = "Naoko Tsuyama and Daisuke Ennishi and Masahiro Yokoyama and Satoko Baba and Reimi Asaka and Yuko Mishima and Yasuhito Terui and Kiyohiko Hatake and Kengo Takeuchi",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.16532",
language = "English",
volume = "8",
pages = "33487--33500",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "20",

}

TY - JOUR

T1 - Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas

AU - Tsuyama, Naoko

AU - Ennishi, Daisuke

AU - Yokoyama, Masahiro

AU - Baba, Satoko

AU - Asaka, Reimi

AU - Mishima, Yuko

AU - Terui, Yasuhito

AU - Hatake, Kiyohiko

AU - Takeuchi, Kengo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Expression of T-cell markers, generally investigated for immunophenotyping of T-cell lymphomas, is also observed in several types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We previously reported that CD5 expression in DLBCL is an inferior prognostic factor in the era of rituximab. However, data regarding the frequencies, histological relevance, and prognostic importance of T-cell markers other than CD5 are currently unavailable. In the present study, we comprehensively evaluated the expression of T-cell markers (CD2, CD3, CD4, CD5, CD7, and CD8) in 501 B-cell lymphomas, including 225 DLBCLs, by flow cytometry and subsequent immunohistochemistry. T-cell markers other than CD5, such as CD2, CD4, CD7, and CD8, were expressed in 27 (5%) patients, and notably, all of these cases were classified as large B-cell lymphoma subtypes: 25 DLBCLs and 2 intravascular large B-cell lymphomas. CD5 and other T-cell markers were expressed in 15% (31/225) and 10% (25/225) of DLBCL cases, respectively. Five of them co-expressed CD5 and other T-cell markers. Retrospectively analyzing the prognostic relevance of T-cell markers in 169 patients with primary DLBCL treated with rituximab-based chemotherapy, we showed that only CD5 was a strong predictor of poor survival. This study provides information about the occurrence of T-cell markers other than CD5 in B-cell lymphomas, their frequent histological subtypes, and their prognostic significance in DLBCL. CD5 was reconfirmed as a negative prognostic marker in DLBCL patients receiving rituximab-inclusive chemotherapy, whereas T-cell markers other than CD5 were found to have no impact on clinicopathological and survival analyses.

AB - Expression of T-cell markers, generally investigated for immunophenotyping of T-cell lymphomas, is also observed in several types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). We previously reported that CD5 expression in DLBCL is an inferior prognostic factor in the era of rituximab. However, data regarding the frequencies, histological relevance, and prognostic importance of T-cell markers other than CD5 are currently unavailable. In the present study, we comprehensively evaluated the expression of T-cell markers (CD2, CD3, CD4, CD5, CD7, and CD8) in 501 B-cell lymphomas, including 225 DLBCLs, by flow cytometry and subsequent immunohistochemistry. T-cell markers other than CD5, such as CD2, CD4, CD7, and CD8, were expressed in 27 (5%) patients, and notably, all of these cases were classified as large B-cell lymphoma subtypes: 25 DLBCLs and 2 intravascular large B-cell lymphomas. CD5 and other T-cell markers were expressed in 15% (31/225) and 10% (25/225) of DLBCL cases, respectively. Five of them co-expressed CD5 and other T-cell markers. Retrospectively analyzing the prognostic relevance of T-cell markers in 169 patients with primary DLBCL treated with rituximab-based chemotherapy, we showed that only CD5 was a strong predictor of poor survival. This study provides information about the occurrence of T-cell markers other than CD5 in B-cell lymphomas, their frequent histological subtypes, and their prognostic significance in DLBCL. CD5 was reconfirmed as a negative prognostic marker in DLBCL patients receiving rituximab-inclusive chemotherapy, whereas T-cell markers other than CD5 were found to have no impact on clinicopathological and survival analyses.

KW - Aberrant expression

KW - CD5

KW - CD8

KW - Diffuse large B-cell lymphoma

KW - T-cell marker

UR - http://www.scopus.com/inward/record.url?scp=85019175083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019175083&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16532

DO - 10.18632/oncotarget.16532

M3 - Article

VL - 8

SP - 33487

EP - 33500

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -